A Longitudinal Study of Skeletal Histomorphometry at 6 and 24 Months Across Four Bone Envelopes in Postmenopausal Women With Osteoporosis Receiving Teriparatide or Zoledronic Acid in the SHOTZ Trial

What Was Tested

This randomized controlled trial paper looks at Teriparatide in the context of osteoporosis and bone density.

Data from the cancellous envelope at month 6 or month 24 provided a reference to compare differences across envelopes within each treatment group.

Why It Was Studied

Previously, the researchers reported the effects of teriparatide (TPTD) and zoledronic acid (ZOL) on bone formation based on biochemical markers and bone histomorphometry of the cancellous envelope at month 6 in postmenopausal women with osteoporosis who participated in the 12-month primary Skeletal Histomorphometry in Subjects on Teriparatide or Zoledronic Acid Therapy (SHOTZ) study.

A second biopsy was performed at month 24.

Who Took Part

The abstract describes 6 women taking part.

By PubMed's age tags, the people studied were middle-aged adults and older adults, women only.

How the Study Was Run

The design is described as randomized.

The women were allocated by chance, so the Teriparatide group and the comparison group should start out alike.

What Was Measured

Previously, the researchers reported the effects of teriparatide (TPTD) and zoledronic acid (ZOL) on bone formation based on biochemical markers and bone histomorphometry of the cancellous envelope at month 6 in postmenopausal women with osteoporosis who participated in the 12-month primary Skeletal Histomorphometry in Subjects on Teriparatide or Zoledronic Acid Therapy (SHOTZ) study.

The 24-month results extend their earlier report that TPTD and ZOL possess different tissue-level mechanisms of action.

The subject headings attached to it are Bone Density, Cancellous Bone, Diphosphonates, Imidazoles, Longitudinal Studies, Osteogenesis and Osteoporosis, Postmenopausal.

The authors tagged it with the keywords ANABOLIC, ANTIRESORPTIVE, TERIPARATIDE and ZOLEDRONIC ACID.

What This Means in Plain Language

The paper is a randomized study of Teriparatide in 6 women in people with osteoporosis and bone density.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2016 (Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research), a journal based in England.

More context: the Teriparatide compound page, Osteoporosis and bone density research.